TETRATHERIX LIMITED (ASX: TTX)
Health care · News and insights
Price unavailable
Latest TTX announcements
Announcement Insights
Tetratherix Enters FY27 With First Revenue And A Broader Commercialisation Push
Tetratherix says FY27 is focused on expanding commercial activity, including FDA clearance efforts and initial sales of bone-regeneration products, after becoming revenue-generating in FY26 through its first commercial STEPP supply. It ended FY26 with $34 million in cash, while a separate October quarter update reported approximately $26 million at quarter-end following an $8 million cash reduction, largely for manufacturing investment and research and development. Recent preclinical tendon-repair results also extend the potential use of TegenEOS beyond bone grafting, while the TetraDerm scar trial is complete but remains blinded.
Updated 12 Nov 2026, 08:47 AM Sydney time
Sources
CEO Address to ShareholdersSTRONGER ECONOMICS, LOCAL ECOSYSTEM EXPANSIONApplication for quotation of securities - TTXQuarterly Activities/Appendix 4C Cash Flow ReportDetails of Auditor Appointment/ResignationTegenEOS Biologic PathwayComments
2026-11-12 · Health care
TTX: $6.40 +0.79% · MC: $340M
At its AGM, Tetratherix outlined FY27 plans to pursue US clearance for its bone regeneration products, followed by market seeding and first regenerative product sales. It also plans to enrol the first patients in Tutelix’s pivotal trial and is selecting a long-term partner for TegenEOS. The company said its manufacturing campus would lift capacity tenfold and that MDSAP certification was now in place, after reporting last month that certification was expected in the coming months.
Updated 2026-11-12 13:31
Sources
CEO Address to ShareholdersComments
2026-11-09 · Health care
TTX: $5.80 +0.00% · MC: $340M
Tetratherix has agreed to pay the University of Sydney a flat royalty of approximately 3% of net product revenue until 2036, replacing tiered royalties, a licence-fee royalty and an indexed minimum royalty. The company says the change is intended to reduce royalties on licensing revenue, simplify administration and provide greater certainty over margins as its products reach market.
Updated 2026-11-09 09:26
Sources
STRONGER ECONOMICS, LOCAL ECOSYSTEM EXPANSIONComments
2026-11-04 · Health care
TTX: $5.55 +0.00% · MC: $340M
Tetratherix has applied to quote ordinary shares issued on conversion of performance rights under its employee incentive scheme. The shares were issued for no cash consideration and will rank equally with existing ordinary shares.
Updated 2026-11-04 11:00
Sources
Application for quotation of securities - TTXComments
2026-10-30 · Health care
TTX: $5.50 +2.80% · MC: $340M
Tetratherix generated its first product revenue after shipping STEPP polymer to US partner Superpower Health, ahead of a planned launch next year. The FDA confirmed core elements of the Tegenix submission but requested further chemical characterisation and labelling details. The company ended the quarter with approximately $26 million in cash after an $8 million decrease, and said TetraDerm trial treatment was complete with results still blinded. Following Nexia’s resignation, BDO was appointed auditor, subject to shareholder approval at the upcoming AGM.
Updated 2026-10-30 15:24
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportDetails of Auditor Appointment/ResignationComments
2026-10-29 · Health care
TTX: $5.35 -2.73% · MC: $340M
Tetratherix says its ten-week preclinical study found better tendon healing with TegenEOS carrying platelet-rich plasma (PRP) than with PRP alone, including more organised blood vessels and less inflammation and scar-like tissue at six weeks. The results extend the potential use of TegenEOS, currently a bone-graft carrier, to delivering biologics for soft-tissue repair; the company says the approach is intended to keep PRP at the injury site as it sets into a gel at body temperature.
Updated 2026-10-29 10:18
Sources
TegenEOS Biologic PathwayComments
Comments